CROSSJECT Aktie
1,11EUR | -0,23EUR | -17,16% |
WKN DE: A1XEH4 / ISIN: FR0011716265
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 93 | 94 | 101 | 110 | 0 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,01 | 0,01 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 18 | 13 | 14 | 11 | 16 |
Summe Anlagevermögen | 15 | 18 | 19 | 18 | 16 |
Summe Aktiva | 34 | 32 | 33 | 29 | 32 |
Bilanz (in Mio. EUR) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 35 | 38 | 31 | 35 | 34 |
Summe Eigenkapital | -1 | -6 | 2 | -6 | -3 |
Summe Passiva | 34 | 32 | 33 | 29 | 32 |
Adresse
6, rue Pauline Kergomard, 21000 Dijon | |
Telefon | +33 (3) 80-54-98-50 |
Internet | http://www.crossject.com |
Management
Daniel Gedeon Teper
Member-Supervisory Board |
Eric Nemeth
Member-Supervisory Board |
Isabelle Liebschütz
Chief Quality & Regulatory Officer |
Jean-Francois Loumeau
Member-Supervisory board |
Olivier Giré
Chief Operating Officer-Specialty Pharma |
Patrick Alexandre
Chairman-Executive Board & Chief Executive Officer |
Philippe Monnot
Chairman-Supervisory Board |
Tony C. Tipton
Chief Operating Officer-United States |
Yannick Plétan
Member-Supervisory Board |